Skip to main content
Premium Trial:

Request an Annual Quote

ERS Genomics Licenses CRISPR Tech to Swiss Firm Cytosurge

NEW YORK – ERS Genomics said on Tuesday that it has signed a nonexclusive license agreement granting Swiss firm Cytosurge access to its CRISPR-Cas9 patent portfolio. Financial details of the agreement were not disclosed.

Cytosurge develops, manufactures, and distributes single-cell research solutions based on patented technology called FluidFM.

The firm also offers a CRISPR cell line engineering service, FluidFM CellEDIT, that is designed for hard-to-transfect cells and complex genome edits. Edits are made on single cells, and customers receive monoclonal cell lines in fewer than 12 weeks.

"We are pleased to support Cytosurge, an exciting and progressive leader in precision single-cell manipulation, in their ongoing developments with this license agreement," ERS CEO Eric Rhodes said in a statement.

ERS Genomics, based in Dublin, was founded to provide access to CRISPR-Cas9 patents held by Emmanuelle Charpentier. The IP is shared with Jennifer Doudna and the University of California, as well as with the University of Vienna.

The company most recently granted nonexclusive licenses to pharmaceutical developers Sumitomo Pharma of Japan and US-based Cellular Engineering Technologies.

In March, the US Patent and Trademark Office found that patents held by the Broad Institute covering CRISPR-Cas9 genome editing technology in eukaryotic cells have priority over similar intellectual property owned by the University of California, the University of Vienna, and Charpentier.

Last month, however, the European Patent Office upheld a CRISPR-Cas9 patent held by ERS Genomics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.